Professional Documents
Culture Documents
Goku Notes: Viral Hemorrhagic Fevers (Bunyaviruses, Arenaviruses, Filoviruses) - Dra. Ma. Ellery Mendez
Goku Notes: Viral Hemorrhagic Fevers (Bunyaviruses, Arenaviruses, Filoviruses) - Dra. Ma. Ellery Mendez
Ellery Mendez
Goku Notes
Page 1
Viral Hemorrhagic Fevers (Bunyaviruses, Arenaviruses, Filoviruses) – Dra. Ma. Ellery Mendez
Goku Notes
No guarantee that
Hemorrhagic Fever Hantavirus Pulmonary patient will live
with Renal Syndrome Syndrome (HPS) Prevention:
(HFRS)
Rodent control
Causes nterstitial 1993 – severe Avoid contact or
nephritis respiratory illness that exposure to rat
Later on results to respiratory droppings
developsrenal failure
failure Starts with flu like ARENA VIRUS
Later on develops illness and
hemorrhage and complicates into
shock serious respiratory “Arena” – sand like (ribosomal particles taken
illness from the host cells and contributes to granular
Novel Hantavirus (also appearance of arenavirus)
known as Sin Nombre
Spherical
which means no name)
Double segmented
Supportive Deer and mouse as
treatment reservoirs Ambisense, single stranded RNA
No guarantee that Ambisense means that this is a genome which
patient will live encodes for proteins and these proteins avoid
Prevented by rodent Signs and Symptoms: creating the double stranded RNA and this
control stops the transcription
Fever Enveloped
Headache
Large club shaped peplomers
Myalgia
Pulmonary edema Replicate in the cytoplasm
No hemorrhage Incorporate into ribosome and bud from the
plasma membrane
Pathogenesis:
Functional impairment
of vascular Multiple Arenavirus cause human disease
endothelium
Virus causes
capillaries to leak Lassa
Results to progressive Junin
fibrosis, pulmonary Machupo
edema and death Guanarito
Laboratory: Sabia
Whitewater-Arroyo
RT PCR – detect the Lymphocytic Choriomeningitis
viral nucleic acid
Immunohistochemistry
ELISA Humans infected when in contact with rodent
Viral isolation is excreta
difficult
Requires containment Infectious aerosols – high level containment
facilities Natural host – rodents
Treatment: Arthropods not involved
Page 3
Viral Hemorrhagic Fevers (Bunyaviruses, Arenaviruses, Filoviruses) – Dra. Ma. Ellery Mendez
Goku Notes
First outbreak – 1967 (Marburg, Germany; Very high titer of virus present in many tissues
Yugoslavia) like:
Liver
Vaccine company was processing primary kidney Spleen
cells from African green monkeys (Cercopithecus Lungs
aethiops). Kidneys
Several works developed a hemorrhagic fever.
Several dozen infected by person to person
transmission FILOVIRUS – Highest mortality of all viral
Fewer than half died hemorrhagic fevers
Filovirus Species Infection confirmed or 1967 – Discovered among lab workers exposed to
suspected African green monkey imported into Germany and
Lake Victoria Marburg Human, monkey, fruit bat Yugoslavia
virus (1980) Transmission from patients to medical personnel
Lake Victoria Marburg with high mortality
Virus (2005)
Cause disease in monkeys and humans, outbreaks
Zaire ebolavirus (1976) Human, monkey (fruit
Zaire ebolavirus (1995) bat, duiker, dog)
Ebola Virus
Cote d’lvoire ebolavirus Human, monkey
(1994)
Bundibugyo ebolavirus human Discovered 1976: severe epidemics of Ebola
(2008) Hemorrhagic Fever
Sudan ebolavirus (1979) human Hospital staff became infected through close and
Sudan ebolavirus (1976) prolonged contact with patients their bodies or
Reston ebolavirus (1989) Monkey, pig (human, excreta
Reston ebolavirus (1992) fruit bat) Person to person transmission
Highly virulent strains: Zaire and Sudan (Zaire is
Manifestations for Marburg and Ebola the most deadly)
Mean time to death from symptom onset: 7-8
Fever days
Headache The 2003 outbreak first recognized in dead
Sore throat gorillas and chimpanzees
Muscle pain followed by abdominal pain In 1989 – Reston strain detected in Macaque
Vomiting monkeys from the Philippines, has low
Diarrhea pathogenicity (infect humans without causing
disease)
Page 4
Viral Hemorrhagic Fevers (Bunyaviruses, Arenaviruses, Filoviruses) – Dra. Ma. Ellery Mendez
Goku Notes
Laboratory
Supportive treatment
No specific antiviral drug
50-90% mortality
Prevention
END
Page 5